Complementary and alternative medicines for the treatment of diabetes

Journal of Pharmacy Practice

Volumn 22, Issue 6, 2009, Pages 546-552

  Tackett, Kimberly L ^a   Jones, Melissa C ^a  

^a SOUTHERN UNIVERSITY   (United States)

Author keywords

Alternative medicine; Complementary and alternative medicine; Diabetes; Herbal medicine

Indexed keywords

ANTIDIABETIC AGENT; BANABA EXTRACT; CAIAPO; CHROMIUM; CHROMIUM PICOLINATE; CINNAMON EXTRACT; COUMARIN DERIVATIVE; GINSENG EXTRACT; GLUCOSE; GYMNEMA SYLVESTRE EXTRACT; NOPAL; PLACEBO; PLANT EXTRACT; PLANT MEDICINAL PRODUCT; PROCYANIDIN TYPE A POLYMER; THIOCTIC ACID; TRIGONELLA FOENUM GRAECUM EXTRACT; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ALTERNATIVE MEDICINE; BARK; BLOATING; CLINICAL TRIAL; COGNITIVE DEFECT; DIABETES MELLITUS; DIABETIC NEUROPATHY; DIARRHEA; DIET SUPPLEMENTATION; DIZZINESS; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FLATULENCE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; GLYCEMIC CONTROL; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; INSULIN SENSITIVITY; KIDNEY DISEASE; LIFESTYLE MODIFICATION; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATIENT SAFETY; PLANT LEAF; PLANT SEED; PLANT STEM; PROPHYLAXIS; REVIEW; SKIN IRRITATION; SWEET POTATO; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

EID: 77949385219     PISSN: 08971900     EISSN: 15311937     Source Type: Journal    
DOI: 10.1177/0897190009332658     Document Type: Review

References (60)

1. Available at: www.CDC.gov. Accessed September 23, 2008.
2. Egede LE, Ye X, Zeng D, et al. The prevalence and pattern of complementary and alternative medicine use in individuals with diabetes. Diabetes Care. 2002;25:324-329.
3. Yeh GY, Eisenberg DM, Kaptchuk TJ, et al. Systematic review of herbs and dietary supplements for glycemic control in diabetes. Diabetes Care. 2003;26:1277-1294.
4. Fox GN, Sabovic Z. Chromium picolinate supplementation for diabetes mellitus. J Fam Pract. 1998;46:83-87.
5. Anderson RA, Cheng N, Bryden NA, et al. Elevated intakes of supplemental chromium improve glucose and insulin variables in individuals with type 2 diabetes. Diabetes. 1997;46:1786-1792.
6. Vincent JB. Quest for the molecular mechanism of chromium action and its relationship to diabetes. Nutr Rev. 2000;58:67-72.
7. Martin J, Wang ZQ, Zhang XH, et al. Chromium picolinate supplementation attenuates body weight gain and increases insulin sensitivity in subjects with type 2 diabetes. Diabetes Care. 2006;29:1826-1832.
8. Kleefstra N, Houweling ST, Bakker SJ, et al. Chromium treatment has no effect in patients with type 2 diabetes in a Western population. Diabetes Care. 2007;30: 1092-1096.
9. ADA. Nutrition recommendations and interventions for diabetes. Diabetes Care. 2008;31(suppl 1):S61-S78.
10. Rodriguez-Fragoso L, Reyes-Esparza J, Burchiel SW, et al. Risks and benefits of commonly used herbal medicines in Mexico. Toxicol Appl Pharmacol. 2008;227: 125-135.
11. Roman-Ramos R, Flores-Saenz JL, Alarcon-Aguilar FJ. Antihyperglycemic effect of some edible plants. J Ethnopharmacol. 1995;48:25-32.
12. Shapiro K, Gong WC. Natural products used for diabetes. J Am Pharm Assoc. 2002;42:217-226.
13. Leach MJ. Gymnema sylvestre for diabetes mellitus: a systemic review. J Altern Complement Med. 2007;13: 977-983.
14. Klein G, Kim J, Himmeldirk K, et al. Antidiabetes and anti-obesity activity of Lagerstroemia speciosa. Evid Based Complement Alternat Med. 2007;4:401-407.
15. Park MY, Lee KS, Sung MK. Effects of dietary mulberry, Korean red ginseng, and banaba on glucose homeostasis in relation to PPAR-a, PPAR-g, and LPL mRNA expressions. Life Sci. 2005;77:3344-3354.
16. Kusano S, Abe H. Antidiabetic activity of white skinned sweet potato (Ipomoea batatas) in obese Zucker fatty rats. Biol Pharm Bull. 2000;23:23-26.
17. Kusano S, Abe H, Tamura H. Isolation of antidiabetic components from white-skinned sweet potato (Ipomoea batatas). Biosci Biotechnol Biochem. 2001;65: 109-114.
18. Ludvik BH, Mahdjoobian K, Waldhaeusl W, et al. The effect of Ipomoea batatas (Caiapo) on glucose metabolism and serum cholesterol in patients with type 2 diabetes. Diabetes Care. 2002;25:234-240.
19. Ludvik B, Neuffer B, Pacini G. Efficacy of Ipomoea batatas (Caiapo) on diabetes control in type 2 diabetic subjects treated with diet. Diabetes Care. 2004;27: 436-440.
20. Ludvik B, Waldhausl W, Prager R, et al. Mode of action of Ipomoea batatas (Caiapo) in type 2 diabetic patients. Metabolism. 2003;52:875-880.
21. Chase CK, McQueen CE. Cinnamon in diabetes mellitus. Am J Health Syst Pharm. 2007;64:1033-1035.
22. Imparl-Radosevich J, Deas S, Polansky MM, et al. Regulation of PtP-1 and insulin receptor kinase by fractions from cinnamon: implications for cinnamon regulation of insulin signaling. Horm Res. 1998;50:177-182.
23. Jarvill-Taylor KJ, Anderson RA, Graves DJ. A hydroxychalcone derivative from cinnamon functions as a mimetic for insulin in 3T3-L1 dipocytes. J Am Coll Nutr. 2001;20:327-336.
24. Anderson RA, Broadhurst CL, Polansky MM, et al. Isolation and characterization of polyphenol type-A polymers from cinnamon with insulin-like biological activity. J Agric Food Chem. 2004;52:65-70.
25. Kahn A, Safdar M, Ali Kahn MM, et al. Cinnamon improves glucose and lipids of people with type 2 diabetes. Diabetes Care. 2003;26:3215-3218.
26. Vanchoonbeek K, Thomassen BJ, Senden JM, et al. Cinnamon supplementation does not improve glycemic control in postmenopausal type 2 diabetes patients. J Nutr. 2006;136:977-980.
27. Baker WL, Gutierrez-Williams G, White CM, et al. Effect of cinnamon on glucose control and lipid parameters. Diabetes Care. 2008;31:41-43.
28. Gail P, Shane-McWhorter L. Dietary supplements in the management of diabetes: potential risk and benefits. J Am Diet Assoc. 2008;108(4 suppl 1):S59-S65.
29. Vuksan V, Sievenpiper JL, Koo VY, et al. American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus. Arch Intern Med. 2000;160:1009-1013.
30. Miller LG. Herbal medicinal: selected clinical considerations focusing on known or potential drug-herb interactions. Arch Intern Med. 1998;158:2200-2211.
31. Liu CX, Xiao PG. Recent advances on ginseng research in China. J Ethnopharmacol. 1992;36:27-38.
32. Yeh GY, Eisenberg DM, Kaptchuk TJ, et al. Systematic review of herbs and dietary supplements for glycemic control in diabetes. Diabetes Care. 2003;26:1277-1294.
33. Sotaniemi EA, Haapakkoski E, Rautio A. Ginseng therapy in non-insulin-dependent diabetic patients. Diabetes Care. 1995;18:1373-1375.
34. Vuksan V, Sun M, Sievenpiper JL, et al. Korean red gensing (Panax ginseng) improves glucose and insulin regulation in well-controlled type 2 diabetes: results of a randomized, double-blind, placebo-controlled study of efficacy and safety. Nutr Metab Cardiovasc Dis. 2008;18:46-56.
35. Tetsutani T, Yamamura M, Yamaguchi T, et al. Can red ginseng control blood glucose in diabetic patients. Ginseng Rev. 2000;28:44-47.
36. Vuksan V, Sievenpiper JL, Xu Z, et al. Konjac-Mannan and American ginseng: emerging alternative therapies for type 2 diabetes mellitus. J Am Coll Nutr. 2001;20 (5 suppl):370S-380S.
37. Vuskan V, Stavro MP, Sievenpiper JL, et al. Similar prostpran-dial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes. Diabetes Care. 2000;23:1221-1226.
38. Konrad T, Vincini P, Kusterer K, et al. a-lipoic acid treatment decreases serum lactate and pyruvate concentrations and improves glucose effectiveness in lean and obese patients with type 2 diabetes. Diabetes Care. 1999;22:280-287.
39. El Midaoui A, de Champlain J. Prevention of hypertension, insulin resistance and oxidative stress by a-lipoic acid. Hypertension. 2002;39:303-337.
40. Ziegler D, Nowak H, Kempler P, et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis. Diabet Med. 2004;21:114-121.
41. Ziegler D, Hanefeld M, Ruhnau KJ, et al. Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multi-centre randomized controlled trial (ALADIN Study). Diabetologia. 1995;38:1425-1433.
42. Ziegler D, Hanefeld M, Ruhnau KJ, et al, and the ALADIN III Study Group. Treatment of symptomatic diabetic polineuropathy with the antioxidant a-lipoic acid. A 7-month multicenter randomized controlled trial (ALDIN III Study). Diabetes Care. 1999;22:1296-1301.
43. Ziegler D, Ametov A, Barinov A, et al. Oral treatment with alpha-lipoic acid improved symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care. 2006;29:2365-2370.
44. Jacob S, Ruus P, Hermann R, et al. Oral administration of RAC-Alpha-lipoic acid modulates insulin sensitivity in patients with type-2 diabetes mellitus: a placebocontrolled pilot trial. Free Radic Biol Med. 1999;27: 309-314.
45. Kamenova P. Improvement of insulin sensitivity in patients with type 2 diabetes mellitus after oral administration of alpha-lipoic acid. Hormones. 2006;5:251-258.
46. Konrad T, Vincini P, Kusterer K, et al. a-Lipoic acid treatment decreases serum lactate and pyruvate concentration and improves glucose effectiveness in lean and obese patients with type 2 diabetes. Diabetes Care. 1999;22:280-287.
47. Vijayakumar MV, Singh S, Chhipa RR, et al. The hypoglycaemic activity of fenugreek seed extract is mediated through the stimulation of an insulin signalling pathway. Br J Pharmacol. 2005;146:41-48.
48. Basch E, Ulbricht C, Kuo G, et al. Therapeutic applications of fenugreek. Altern Med Rev. 2003;8:20-27.
49. Al-Habori M, Raman A. Antidiabetic and hypocholesterolaemic effects of fenugreek. Phytother Res. 1998;12: 233-242.
50. Gupta A, Gupta R, Lal B. Effect of Trigonella foenumgraecum (fenugreek) seeds on glycaemic control and insulin resistance in type 2 diabetes mellitus: a double blind placebo controlled study. J Assoc Physicians India. 2001;49:1057-1061.
51. Raghuram TC, Sharma RD, Sivakumar B, et al. Effect of fenugreek seeds on intravenous glucose disposition in non-insulin dependent diabetic patients. Phytother Res. 1994;8:83-86.
52. Sharma RD, Raghuram TC. Hypoglycaemic effect of fenugreek seeds in non-insulin dependent diabetic subjects. Nutr Res. 1990;10:731-739.
53. Sharma RD, Sarkar A, Hazra DK, et al. Use of fenugreek seed powder in the management of non-insulin dependent diabetes mellitus. Nutr Res. 1996;16: 1331-1339.
54. Kuppu RK, Srivasta A, Krishnaswami CV, et al. Hypoglycemic and hypotriglyceridemic effects of methika churna (fenugreek). Antiseptic. 1998;95:78-79.
55. Madar Z, Abel R, Samish S, et al. Glucose lowering effect of fenugreek in non-insulin dependent diabetes. Eur J Clin Nutr. 1988;42:51-54.
56. Sharma RD. Effect of fenugreek seeds and leaves on blood glucose and serum insulin responses in human subjects. Nutr Res. 1986;6:1353-1364.
57. Sharma RD, Raghuram TC, Rao NS. Effect of fenugreek seeds on blood glucose and serum lipids in type I diabetes. Eur J Clin Nutr. 1990;44:301-306.
58. American Diabetes Association. Patient information: guidelines for using vitamin, mineral and herbal supplements. Diabetes Spectrum. 2001;14:160.
59. American Diabetes Association. Patient information: a step-by-step approach to complementary therapies. Diabetes Spectrum. 2001;14:225.
60. American Diabetes Association. Unproven therapies (Position Statement). Diabetes Care. 2002;25:S133.